Tango Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $62.4 | $42.1 | $36.5 | $24.9 | $37.0 |
| Operating income | -$111.3 | -$145.6 | -$114.2 | -$111.1 | -$58.2 |
| Net income | -$101.6 | -$130.3 | -$101.7 | -$108.2 | -$58.2 |
| Cash Flow Statement | |||||
| Free cash flow | -$139.9 | -$132.3 | -$119.5 | -$116.8 | -$61.4 |
| Share repurchases | — | — | $0.7 | — | — |
Shares outstanding 168.6M · Free float 66.2%
Annual filing data through FY ended December 31, 2025; float as of October 5, 2026.